Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free VCNX Stock Alerts
NASDAQ:VCNX

Vaccinex (VCNX) Stock Price, News & Analysis

Vaccinex logo
$1.00 0.00 (0.00%)
As of 09/18/2026
Compare

About Vaccinex Stock (NASDAQ:VCNX)

View Price History Chart DataSkip Price History Chart
Advanced
1 Day 5 Days 30 Days 90 Days 1 Year
Advanced

Key Stats

Today's Range
$1.00
▼
$1.00
50-Day Range
$0.72
▼
$1.25
52-Week Range
$0.31
▼
$1.50
Volume
71 shs
Average Volume
3,159 shs
Market Capitalization
$2.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vaccinex, Inc. (NASDAQ:VCNX) is a clinical-stage biotechnology company developing antibody-based therapies for neurodegenerative diseases and cancer. The company uses its proprietary ActivMAb antibody-discovery platform to identify and develop monoclonal antibodies directed at challenging therapeutic targets.

Vaccinex’s lead product candidate is pepinemab, an antibody designed to inhibit semaphorin 4D (SEMA4D), a protein involved in immune regulation, inflammation, and tissue damage. The company has evaluated pepinemab in clinical studies involving conditions including Huntington’s disease, Alzheimer’s disease, multiple sclerosis, and certain cancers, with development focused on potential treatments for neurological and immuno-oncology indications.

Vaccinex is headquartered in Rochester, New York, and its programs are developed through clinical research collaborations and trials conducted in the United States and other locations. Maurice Zauderer, Ph.D., is the company’s co-founder, president, and chief executive officer.

AI Generated. May Contain Errors.

Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VCNX Stock News Headlines

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.tc pixel
September 22 at 1:00 AM  |  Porter & Company (Ad)
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
Vaccinex announces $60M revenue sharing agreement with PDV
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/vaccinex-announces-60m-revenue-sharing-agreement-with-pdv/ar-AA1SUmDZ
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease-1035667359
Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment
December 23, 2025  |  quiverquant.comQ
See More Headlines

VCNX Stock Analysis - Frequently Asked Questions

Vaccinex's stock was trading at $1.0755 on January 1st, 2026. Since then, VCNX shares have decreased by 7.0% and is now trading at $1.00.

Vaccinex, Inc. (NASDAQ:VCNX) announced its earnings results on Monday, November, 8th. The company reported ($35.70) earnings per share for the quarter, beating the consensus estimate of ($60.90) by $25.20. The firm earned $0.05 million during the quarter.

Vaccinex shares reverse split on Tuesday, February 20th 2024.The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Vaccinex (VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include Pfizer (PFE), VBI Vaccines (VBIV), OPKO Health (OPK), Plug Power (PLUG), NIO (NIO) and SNDL (SNDL).

Company Calendar

Last Earnings
11/08/2021
Today
9/22/2026
Next Earnings (Estimated)
11/16/2026
Fiscal Year End
12/31/2026
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VCNX
CIK
1205922
Web
www.vaccinex.com
Phone
(585) 271-2700
Fax
585-271-2765
Employees
40
Year Founded
2001

Profitability

EPS (Trailing Twelve Months)
($48.27)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.25 million
Net Margins
N/A
Pretax Margin
-4,787.89%
Return on Equity
N/A
Return on Assets
-383.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.77
Quick Ratio
0.77

Sales & Book Value

Annual Sales
$388 thousand
Price / Sales
6.70
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.59) per share
Price / Book
-0.39

Miscellaneous

Outstanding Shares
2,600,000
Free Float
1,261,000
Market Cap
$2.60 million
Optionable
No Data
Beta
1.10

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:VCNX) was last updated on 9/22/2026 by MarketBeat.com Staff.
From Our Partners
The AI Infrastructure Rush Is ON — Watch VDTA
Vertical Data Inc. (OTCQB: VDTA) is targeting the infrastructure layer beneath the AI boom, from GPU hardware ...
Trading Wire | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
This AI Stock Reminds One Analyst of Early Nvidia
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
A quantum leap and how to play it
AI compute and biotech are colliding at unprecedented speed. Development timelines are collapsing by up to 80 ...
Porter & Company | Sponsoredtc pixel